Results for the year ended 30 September 2019
10 December 2019
RWS Holdings plc
Results for the year ended 30 September 2019
Record performances across all three main businesses
RWS Holdings plc ("RWS", "the Group"), one of the world's leading language, intellectual property support services and localization providers, today announces its final results for the year ended 30 September 2019.
Financial highlights
Strong growth and increased margins drove results ahead of consensus market forecasts
|
|
2019 |
2018 |
Change |
|
Revenue |
£355.7m |
£306.0m |
+16% |
|
|
|
|
|
|
Adjusted operating profit[1] |
£78.4m |
£66.3m |
+18% |
|
Adjusted profit before tax1 |
£74.2m |
£61.8m |
+20% |
|
Reported profit before tax |
£57.7m |
£39.7m |
+45% |
|
|
|
|
|
|
Adjusted earnings per share1 |
21.3p |
17.4p |
+22% |
|
Basic earnings per share |
16.5p |
10.4p |
+59% |
|
|
|
|
|
|
Dividend |
|
|
|
|
Proposed final |
7.0p |
6.0p |
+17% |
|
Total for year |
8.75p |
7.5p |
+17% |
|
|
|
|
|
|
Net Debt1 |
£36.8m |
£65.1m |
-43% |
Highlights
· Growth in sales and profits across all three main divisions
· Language Solutions' acquisition of Alpha Translations Canada Inc., a specialist legal translations provider
· Opening of new Moravia head office in Brno, Czech Republic
RWS Moravia
· Record revenues of £149.9m (2018: £126.9m) and record adjusted operating profit growth of 52% to £25.7m (2018: 11 months, £17.0m).
· As a leading provider of technology-enabled localization services, this business has consistently focused on developing, innovating and investing in its services to drive future growth both from existing customers, which include many of the largest technology companies, and from an increasing cadre of new clients.
RWS IP Services
· Strong growth in revenues, up 12% to £125.2m (2018: £111.9m) driven by Eurofile and Worldfile divisions.
· Excellent performance in Asia Pacific, a key area of focus for growth in future years.
· Investment across departments to enable more efficient management of increasing volumes of business.
· Adjusted operating profit increased to £36.1m (2018 £34.4m).
RWS Life Sciences
· Highest divisional growth in revenues at 25%, advancing to £65.5m (2018: £52.3m), driven by growth in linguistic validation services and the transfer of Moravia Life Science clients effective 1 October.
· Adjusted operating profit increased to £20.3m (2018: £14.5m).
Outlook
· Underlying performance in the first two months has been in line with the Board's expectations, but the sharp increase in the GBP/USD exchange rate is clearly unhelpful.
· Excellent pipeline of new clients in IP Services.
· With all of the Group's integration plans now executed, we are well positioned to convert a wide range of sales opportunities across our full suite of services and technology platforms.
Andrew Brode, Chairman of RWS, commented:
"This has been another remarkable year for the Group, delivering our 16th year of unbroken growth in revenues, profits and dividends since flotation in November 2003.
"We were delighted that RWS was named Company of the Year at the recent AIM Awards and that our three main divisions delivered record performances. We also strengthened our specialist legal and financial translation offering through the acquisition of Alpha Translations Canada Inc.
"The Group has now consolidated its position as one of the world's leading providers of language services and is taking advantage of the many opportunities provided by our extensive service offerings, broadened client base, expanded global presence and the demand for our specialist intellectual property, life sciences and localization services. Our strong balance sheet also ensures that we remain well positioned in the pursuit of further acquisition opportunities.
"We look forward with confidence to achieving further progress in 2020."
For further information, please contact:
|
RWS Holdings plc Andrew Brode, Chairman Richard Thompson, Chief Executive Officer Des Glass, Chief Financial Officer
|
01753 480200 |
|
MHP Katie Hunt/Simon Hockridge |
0203 128 8100
|
|
Numis (Nomad & Joint Broker) Stuart Skinner/Kevin Cruickshank/Michael Burke
|
0207 260 1000 |
|
Berenberg (Joint Broker) Ben Wright/Toby Flaux/Alix Mecklenburg-Solodkoff
|
0203 207 7800 |
|
About RWS: RWS is the world's leading provider of intellectual property support services (patent translations, international patent filing solutions and searches), a market leader in life sciences translations and linguistic validation, a leading localization provider, and a high-level specialist language service provider in other technical areas, providing for the diverse needs of a blue-chip multinational client base from Europe, North America and Asia.
RWS is based in the UK, with offices in Europe, North America, Asia, Latin America and Australia, and is listed on AIM, the London Stock Exchange regulated market (RWS.L).
For further information, please visit: www.rws.com
Forward-Looking Statements This announcement contains certain statements that are forward-looking statements. They appear in a number of places through this announcement and include statements regarding our intentions, beliefs or current expectations and those of our officers, directors and employees concerning, amongst other things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the business we operate. By their nature, these statements involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and, unless otherwise required by applicable law, the Company undertakes no obligation to update or review these forward-looking statements. Nothing in this announcement should be construed as a profit forecast. The Company and its directors accept no liability to third parties in respect of this document save as would arise under English law.
|
|
Chairman's Statement
Introduction
RWS, which celebrated its 61st year in business in 2019, has grown to become one of the world's leading providers of language services. Following the transformational acquisition of Moravia in November 2017, the Group now employs over 2,500 people with operations across five continents. In recognition of our recent progress, we were delighted to be named Company of the Year at this year's recent AIM Awards.
We announced in June 2015 that our strategy for growth would focus on the United States to 2020, and that beyond 2020 we believed that China would become an important area for growth. Since that announcement, RWS has made four acquisitions with a US focus and built market-leading activities in intellectual property support services, in life sciences and in technology-enabled localization. Looking forward, China shows every sign of fulfilling the strategic growth potential we envisaged in 2015.
Performance
The Group achieved revenues of £355.7m for the year, growing 16% from 2018 (£306.0m). All three of our major divisions delivered increased revenues and profits, contributing to 7% underlying[2] organic sales growth across the Group (excluding the impact of acquisitions and currency movements).
Adjusted profit before tax grew by 20% to £74.2m (2018: £61.8m). Adjusted profit before tax increased by 14% on an underlying organic basis (excluding the impact of acquisitions and currency movements). This reflected particularly strong underlying increases in margins in our Life Sciences and Moravia divisions, due to a combination of sales growth, a greater proportion of higher margin revenues, tight cost control and positive exchange rate movements.
The Group's balance sheet expanded with net assets of £397.5m (2018: £355.3m). Net debt reduced to £36.8m (2018: £65.1m) emphasizing our cash generative business model: leverage at year-end (net debt: EBITDA) was less than 0.5 EBITDA[3]. I am again proud to report that RWS has increased revenues, profits and dividends in every year since flotation in November 2003.
People and Board
The Group could not have advanced to its current position as a leading global language service provider, without the commitment of all our colleagues, and I would like to thank them and to acknowledge their part in our success. RWS epitomizes a knowledge-based "people" business, intent upon providing a superior quality of service to a large number of the world's leading and most demanding clients. The Board is committed to continuing investment in the development of our staff to enable them to realize their full potential.
My thanks are also due to my fellow directors for their advice and dedication. The role of a non-executive director, in particular, has become more onerous as they deal with increasing levels of reporting requirements, both external and internal.
Environmental, Social and Corporate Governance (ESG)
On 29 September 2018, RWS adopted the QCA Corporate Governance Code.
The Group has devoted significant resources to improving its environmental responsibilities. Similarly, we have sought to engage more with our staff and the wider group of external stakeholders, including through our partnership with The University of Manchester, to sponsor students from lower income families reading for language degrees, and our sponsorship scheme for schools to send students on Outward Bound Trust events. The schools selected are in lower economic areas and were selected only if they had a firm commitment to teaching languages. We have been pleased with the reaction we have received to date.
Dividend
Since flotation in November 2003, RWS has pursued a progressive dividend policy. The highly cash generative business model and modest capex requirements have allowed for rapid debt repayment, acquisitions, continued organic investment in the business and an increasing dividend.
The Board therefore is pleased to recommend a final dividend of 7.00p per share, which, together with the interim dividend of 1.75p per share, will result in a total dividend for the year ended 30 September 2019 of 8.75p per share, an increase of 17% compared to 2018. Subject to shareholder approval at the next AGM, it will be paid on 21 February 2020 to shareholders on the register as at 24 January 2020.
Summary and Outlook
This has been another excellent year for RWS, delivering profitable organic growth and enviable cash conversion.
The Group is now a well-balanced and integrated business with an extensive service offering and a global presence. We have strong platforms to exploit opportunities across our full suite of services and technological capabilities for new and existing clients.
The new year has begun in line with our underlying expectations, albeit with recent currency headwinds. Our three main divisions, all leaders in their respective spaces, are well positioned to take advantage of the excellent opportunities in their growing markets. Our strong balance sheet and minimal net debt also positions us well to compete for the most attractive acquisition opportunities in our space.
Despite widespread economic and political uncertainty, I take much pleasure in chairing a fast expanding Group which is an acknowledged leader in a growing business sector.
Andrew Brode, Chairman
9 December 2019
Strategic Report
RWS is one of the world's leading providers of language services, focusing on key market segments where the quality of its services is of critical importance to its clients. The Group has a blue-chip multinational client base spanning Europe, North America and Asia.
With effect from 1 October 2018, RWS Patent Information and RWS Patent Translation and Filing were combined to create the RWS IP Services division. As a result, the Group operated as four divisions throughout the 12 months ended 30 September 2019:
> RWS IP Services is the world's premier supplier of patent translations and filing solutions, offering a seamless global patent filing experience and a wide range of cutting-edge intellectual property (IP) search services. RWS differentiates itself from the competition through the quality of its translations, its high level of intellectual property expertise, its customer service and its use of technology, including:
• inovia, its international web-based patent filing platform;
• Patbase, one of the world's largest searchable commercial patent databases, designed by professional searchers for professional searchers; and
• AOP Connect™ our global connection to our Crowd of +43,000 researchers, allowing customers to store, review, search full-text, rank, highlight and organize intellectual property prior art all in one central location.
> RWS Life Sciences focuses solely on the language service needs of the life sciences market, providing technical translations and linguistic validation to large pharmaceuticals and clinical research organizations in North America, Europe and Asia. This division was formed on 1 October 2017 following the integration of two acquired businesses, CTi and LUZ.
> RWS Moravia works with many of the world's largest publicly traded technology companies to manage their complex localization needs and ensure brand consistency on a global scale. This includes the adaptation of content, software, websites, applications, marketing materials and audio/video for hundreds of languages and geographies. Moravia was acquired in November 2017.
> RWS Language Solutions operates from the UK, Germany and the US, and provides commercial translation solutions with an emphasis on technical translations, as well as operating the Group's interpreting service. During the year RWS acquired Alpha Translations Canada Inc., a company based in Canada that provides predominately legal translations for the German market.
With effect from 1 October 2019, RWS Language Solutions was merged into RWS Moravia. In future, we will report on their performance as one segment, RWS Moravia.
Our strategy
We are focused on providing an increasing range of appropriate services to existing and new clients to drive organic growth. This growth is supplemented by selective acquisitions that are complementary to our existing business and either add additional services or increase RWS's geographical coverage to support our customers and enhance shareholder value.
Organic growth is driven by:
> the growing demand for language services driven by globalization and international trade
> an increase in the worldwide patent filing activities of existing multinational clients
> the development of new drugs by the pharmaceutical industry
> the outsourcing by corporates, clinical research organizations, law firms and attorneys of all or part of their foreign patent search, filing, translation, localization and linguistic validation processes
> the growth in digital content generated internationally and requiring quality localization
> the Group's use of technology that enables RWS to provide customers with a world leading augmented translation service, incorporating the latest IT developments for the language service sector
> the Group's ability to attract new clients by its leading position and reputation in an otherwise highly fragmented sector
> the Group's ability to expand in new or existing but growing geographies
> an increase in cross divisional selling of the Group's suite of services
In terms of acquisitions, we look for selective opportunities in the intellectual property services and specialist language services spaces. We seek businesses capable of delivering above average industry levels of profitability or, are highly complementary, and are capable of reinforcing the Group's dominant position in intellectual property support and language services.
We are particularly pleased to be able to show our progress against this strategy with 16 consecutive years of growth in revenues and profits since flotation.
|
IP Services |
£125.2m Revenues up 12% |
|
Life Sciences |
£65.5m Revenues up 25% |
|
Moravia |
£149.9m Revenues up 18% |
|
Language Solutions |
£15.1m Revenues up 1% |
|
Total |
£355.7m Revenues up 16% |
Global language services market
In July 2019, Common Sense Advisory ("CSA") published its 15th study of the market for outsourced language services. This year the market is estimated to reach US$49.6bn (2018: US$46.5bn), continuing the unbroken growth record since 2009 (CAGR: 7.8%). Increased demand for content from a growing and increasingly interconnected world continues to fuel this demand for high-quality translation and localization.
For the next three years CSA is forecasting CAGR of 4.2% worldwide
Global life sciences market
Global health care spending is projected to reach $10 trillion by 2022. It is projected to increase at an annual rate of 5.4% in 2018-2022, a considerable rise from 2.9% in 2013-2017. This increase partly reflects the expansion of health care coverage in developing markets, the growing care needs of elderly populations and advances in treatments and health technologies.
Similar with recent years, health care spending in 2020 will likely be driven by the shared factors of ageing and growing populations, developing market expansion and clinical and technology advances. In addition, the trend towards universal health care is expected to continue, with more countries expanding or deepening their public health care systems.
For pharmaceutical/biotechnology, medical device companies and contract research organizations, this will mean more content that needs to be translated.
(Source: Deloitte, 2019 Global Life Sciences Outlook)
Patent filing statistics
The World Intellectual Property Organization (WIPO) has published figures showing a +3.9% worldwide increase in patent applications filed under the Patent Cooperation Treaty (PCT) in 2018. This is the ninth consecutive year of growth, with approximately 253,000 applications being received. The largest number of filers continue to be located in the United States, but the number of applications from Asia has continued to grow and, for the first time, applicants originating from this region accounted for the majority of all PCT applications (50.5%). The European Patent Office (EPO) reports European patent applications remained at record levels with 174,317 received in 2018 - an increase of 4.6%.
(Sources: Patent Cooperation Treaty Yearly Review 2019, EPO Annual Report 2018)
Operating review
RWS IP Services
On 1 October 2018, RWS Patent Translation and Filing division and RWS Patent Information division were merged to form the RWS IP Services division. The comparative figures below reflect this consolidation.
The Group's IP Services division represented 35% of Group sales in the year and grew reported revenues by 12% to £125.2m (2018: £111.9m). This performance reflects the full year effect of client wins in prior periods, good new business wins in the year, strong organic growth from the established client base in both our Worldfile (+8%) and Eurofile services (+17%), as well as further strong growth in China (+21%) and Japan (+19%), offset partly by customer losses. In addition, PatBase grew revenues (+6%) through a combination of price increases and new business wins.
During the year, the division achieved several new client wins, including a notable pharmaceutical client that has generated significant new revenue for the business in the period. The Group also benefitted from a favourable exchange rate environment; the division's underlying sales growth is 10%.
The division's strong order pipeline, combined with the record numbers of new patent applications in 2018 (see Market update), provides firm grounds for confidence in the outlook for FY 2020.
The Asia market continues to be a key focus for long-term strategic revenue growth as the region continues to attract North American and European patent filers seeking patent protection. In addition, the IP Services division is seeing rapid growth in the local Asia market as we successfully develop new business with both local companies and patent attorneys. To support this growth RWS continues to invest in the region and has recently opened a new Group office in Tokyo to house the staff from all three divisions. This investment will improve inter-divisional communication, sales collaboration, staff recruitment and facilitate the sharing of best practice.
The division's increased revenue resulted in adjusted operating profit up 5% to £36.1m (2018: £34.4m), driven by revenue growth and a tight control of overheads. This was partly offset by additional investment in staffing, to both manage the growth in business, particularly Eurofile, and to create an improved working environment for the staff within the Chalfont St Peter Head office, to encourage them to build long term careers with RWS and reduce staff churn.
RWS Life Sciences
The Group's Life Sciences division accounted for 19% of the Group's sales in the year. Revenue of £65.5m represented an increase of 25% over the prior period (2018: £52.3m). The 2019 reported results benefitted from favourable exchange rates and growth from the additional Life Science customers acquired with Moravia, that were transferred to RWS Life Sciences with effect from 1 October 2018 (2018: US$6.0m). The underlying sales growth of the division was 10%.
Following a slow start to the year and a change in divisional leadership, the business recovered strongly, led by sales of the division's higher margin Linguistic Validation offering, which grew by 24% in constant currency terms. Sales to the division's largest customer grew by 9% in constant currency. Sales of general Life Science services were flat (in constant currency and after excluding the Moravia Life Science business transferred in) and plans are in place to improve this in 2020. Sales to the former Moravia Life Science customers improved by 10% in the period, highlighting the value of transferring these customers into the specialist RWS Life Sciences division.
The outlook for the division is encouraging, with continued good opportunities in Linguistic Validation, good progress on the Machine Translation (MT) project with the division's largest customer and signs of improvement in the general Life Sciences business, not least with Medical Device translations, where we are beginning to see a positive impact on work volumes arising from the new European Union Medical Device requirements.
The division continues to invest and expand in Asia to capitalize on the market growth and to better serve its customers. During the year the division achieved its first contract win with a local China based pharmaceutical company.
The division improved its margin in the period reporting an adjusted operating profit of £20.3m, an increase of 40% over the prior year (2018: £14.5m). This outstanding result was driven by stronger gross margins, partly from tight operational control but also from having a higher proportion of higher margin Linguistic Validation sales, the impact of the transferred Moravia business and a positive exchange rate environment.
RWS Moravia
The RWS Moravia division accounted for 42% of Group sales, with revenue of £149.9m (2018: £126.9m), an 18% increase over the prior period. The difference being due to a strong sales performance, particularly with customers outside the 'top 5', a shorter comparative trading period of 11 months, the transfer of Life Science customers to the RWS Life Sciences division and favourable exchange rates in the year. The underlying sales growth is 7%.
The 7% underlying sales growth was achieved despite the ongoing reduction in volumes with one of the division's top five customers, excluding which sales across the rest of the division increased by 12% in constant currency terms. It was particularly encouraging to see significant growth in revenue from customers outside the 'top 5'.
The division recorded an adjusted operating profit of £25.7m an increase of 52% over the prior period (2018: £17.0m), reflecting an extra month's trading in 2019, good sales growth, significant margin improvements, tight control of overheads and a foreign exchange tailwind. The underlying profit growth in the period is estimated to be 17%.
One of the highlights of Moravia's year was the official opening of the division's new head office in Brno, Czech Republic. This investment brings together all of the Brno team under one roof for the first time since 2006 and will result in better communication, improved efficiency and innovation.
The outlook for the division for FY 2020 remains positive, and further investment is being made in technology and new services to ensure that the division remains at the forefront of the language services and localization market.
RWS Language Solutions
The RWS Language Solutions division accounted for 4% of Group sales, with revenue of £15.1m (2018: £14.9m) reflecting a tougher year for this, the smallest of RWS's divisions and the one most exposed to competition. The business has experienced adverse trading conditions in its core markets, particularly in the German automotive and renewable energy sectors, both of which have reduced expenditure on translation services.
During the period management have worked on standardizing and rationalizing the operational processes across the division, which will result in improved efficiencies in terms of workload balancing, which, in turn, will improve margins.
On 17 January 2019, the Group announced the acquisition of Alpha Translations Canada Inc. This business focuses on the German legal translation market and provides the division with a new North American operational centre. The acquisition is already fully integrated into RWS and has generated some strong cross selling opportunities.
On 1 October 2019, the Language Solutions division was merged into RWS Moravia and going forward financial results will be reported as one business segment. This change will more closely align these two businesses given their similar services, albeit at different scales and the relatively small size of the Language Solutions business. It is expected that Moravia's experience and knowledge of Machine Translation will further enhance the service levels and efficiencies of the Language Solutions Business.
With a small increase in revenue and lower margins, the adjusted operating profit fell to £0.4m (2018: £1.6m).
Risk Management
The Group considers a risk management framework as a vital tool to ensure existing and potential risks to the business are identified and mitigating actions are fully considered. The framework covers the extended business, including the Group's supply chain, from key suppliers to end-clients. The CFO is charged with both identifying the broad market related risks to the Group and collating specific potential risks from the divisional Managing Directors for further assessment via the risk management framework.
Opportunities for the Group are assessed by the CFO in terms of potential financial benefit and return on investment, where appropriate.
The risk management framework categorizes potential risks to the business, first by considering the risk area and the specific identified risk, before applying an impact analysis that ranks the significance of the risk with the probability of the risk occurring to produce a gross risk score. This is then filtered against the mitigating controls before identifying any further action that is required to minimize the potential risk to the business. At the end of this process a net risk is assessed, and a risk owner assigned, along with an expected timetable to complete any identified further action.
The deliverable from this process is an official risk register which is reviewed and assessed on a bi-annual basis by the Board. The Group believes that it has fostered an open and proactive culture to risk management throughout its divisional structure and has recently strengthened this process further through the introduction of a half yearly review of the formal risk register by the senior management team, with any updates approved by both the CFO and the CEO.
Currently, the key risks included within the risk register are as follows: maintaining the quality of the Group's services; a mismatch between currencies (especially between the USD and GBP); regulatory changes to patent translation requirements in Europe; the emergence of new translation technologies; and the failure to successfully integrate acquired businesses into RWS. Additionally, as with any people business delivering high-quality services, the Group depends upon its ability to attract and retain well-trained management and staff. The risk of Brexit on our ability to attract and retain staff from the European Union remains unknown.
These risks are mitigated as follows:
> Failings in service provision could arise as a result of human error. RWS was the first language services provider and the first search company to adopt ISO certification. The Group also has extensive ISO certified processes in its Life Sciences and Moravia divisions and invests in exhaustive and regularly updated procedures to minimize the risk of error, leading to consistently high levels of accuracy. In addition, the Group carries substantial professional indemnity insurance.
> Currency risk is partly mitigated via hedging operations and matching dollar denominated debt to US revenues.
> We have in the past drawn the market's attention to the proposed European Union Patent ("the Unitary Patent" or "UP") and its potential impact upon the Group's profits and the uncertainty around the timetable for its implementation. It remains unclear when the UP system will start as the date is dependent upon ratification of the UP agreement by the German authorities. This ratification is being delayed by a legal appeal to the German courts, claiming the UP is unconstitutional under German law. It is now expected that this case will be heard in the first quarter of calendar year 2020. However, even if the complaint is dismissed, this does not necessarily mean Germany will immediately complete the ratification process as the German authorities are expected to want to understand the consequences for the UP, if the UK withdraws from the European Union ("Brexit").
Broadly, if the UP agreement is not ratified by the Brexit date, the UK would be outside the UP, further reducing its benefits to RWS's clients. If it is ratified prior to the Brexit date, further discussions would need to take place to agree whether the UK could remain in the UP when it is not part of the European Union.
It is worth highlighting that when eventually implemented, the territorial coverage of the proposed UP will not be as comprehensive as the current, long-established patent application procedures, and will run in parallel with this system. It will also have a different litigation process and fee structure. As such, we believe our major clients will be cautious in their take-up of this new and unproven system and will decide upon their patenting strategies as they observe the UP in action, assessing which of the two systems they prefer for their filings. As a result of the above, we do not expect the UP to have any impact on our FY 2020 financial results and a limited impact in subsequent years.
> The Group has always embraced new translation technologies, such as Translation Memory ("TMs"), and used them to good effect in order to maintain and improve margins, efficiency and competitiveness. Recognizing the advances in Machine Translation technology ("MT"), we continue to monitor, trial its use and introduce MT into the business where it makes commercial sense to do so and where there is significant additional benefit beyond our existing TM. Moravia utilizes a comprehensive range of MT technologies as an integrated part of its services to its technology clients, and its extensive knowledge of these technologies is currently being leveraged across the broader Group. It is clear that the quality of MT will improve over time and as a leader in language services, RWS will continue to differentiate itself by focusing on translation work in critical areas such as intellectual property and life sciences or where the nuances of localization are highly valued by major global brands.
> In recent years, RWS has acquired and integrated several businesses into the Group successfully:
o In October 2015, RWS acquired Corporate Translations Inc. (CTi) and subsequently integrated RWS's smaller existing life sciences businesses of PharmaQuest and its Medical Translation division into the newly acquired business. This integration work was completed in September 2016.
o In February 2017, RWS acquired LUZ, Inc, and the integration of this business with the existing life sciences businesses to form the united RWS Life Sciences division was completed in October 2017.
o In November 2017, RWS acquired Moravia, which included a small life sciences division, with US$6m of revenue. The integration of this business into the RWS Life Sciences division was completed in September 2018.
o In February 2019, RWS acquired Alpha Translation Inc. This business has been fully integrated into RWS Language Solutions, which from 1 October 2019 has been integrated into RWS Moravia.
The framework developed for integrating acquired businesses is now well established at RWS and the experience and knowledge gained from the above integrations will continue to be utilized on future acquisitions.
> RWS has been successful in recruiting high calibre staff to support our growth to date. However, competition for talent in key cities, such as London, is intensifying. In order to continue to grow our global talent base, we strive to offer stability of employment, competitive salaries and an excellent working environment to our colleagues and, where appropriate, to add locations in second cities that provide access to a wider talent pool. In addition, the Group has taken steps to make RWS a better place to work, with the introduction of events such as 'well being' weeks, A green environmental week and establishing a Save as You Earn scheme for UK employees and it is pleasing to note the significant reduction in staff churn in 2019 at our Buckinghamshire head office.
Richard Thompson
Chief Executive Officer
9 December 2019
Consolidated Statement of Comprehensive Income
for the year ended 30 September 2019
|
|
Note |
2019 |
2018 £'000 |
|
Revenue |
3 |
355,696 |
306,044 |
|
Cost of sales |
|
(213,210) |
(187,211) |
|
Gross profit |
|
142,486 |
118,833 |
|
Administrative expenses |
|
(80,606) |
(74,702) |
|
Operating profit |
|
61,880 |
44,131 |
|
Analysed as: |
|
|
|
|
Operating profit before charging: |
|
78,396 |
66,310 |
|
Amortization of acquired intangibles |
|
(15,414) |
(14,591) |
|
Acquisition costs |
|
(791) |
(7,588) |
|
Share based payment expense |
|
(311) |
- |
|
Operating profit |
|
61,880 |
44,131 |
|
Finance income |
|
105 |
69 |
|
Finance costs |
|
(4,268) |
(4,541) |
|
Profit before tax |
|
57,717 |
39,659 |
|
Taxation |
4 |
(12,577) |
(11,402) |
|
Profit for the year |
|
45,140 |
28,257 |
|
Other comprehensive income/(expense)* |
|
|
|
|
Gain on retranslation of foreign operations |
|
20,141 |
3,526 |
|
(Loss)/gain on cash flow hedges |
|
(2,661) |
408 |
|
Total other comprehensive income |
|
17,480 |
3,934 |
|
Total comprehensive income attributable to: |
|
|
|
|
Owners of the Parent |
|
62,620 |
32,191 |
|
|
|
|
|
|
Basic earnings per ordinary share (pence per share) |
6 |
16.5 |
10.4 |
|
Diluted earnings per ordinary share (pence per share) |
6 |
16.4 |
10.4 |
*Other comprehensive income includes only items that will be subsequently reclassified to profit before tax when specific conditions are met.
Consolidated Statement of Financial Position
at 30 September 2019
|
|
Note |
2019 £'000 |
2018 £'000 |
|
Assets |
|
|
|
|
Non-current assets |
|
|
|
|
Goodwill |
|
249,421 |
233,236 |
|
Intangible assets |
|
169,109 |
172,517 |
|
Property, plant and equipment |
|
22,888 |
21,961 |
|
Deferred tax assets |
|
3,371 |
2,081 |
|
|
|
444,789 |
429,795 |
|
Current assets |
|
|
|
|
Trade and other receivables |
|
85,543 |
72,656 |
|
Foreign exchange derivatives |
|
- |
1,014 |
|
Cash and cash equivalents |
|
46,974 |
38,155 |
|
|
|
132,517 |
111,825 |
|
Total assets |
3 |
577,306 |
541,620 |
|
Liabilities |
|
|
|
|
Current liabilities |
|
|
|
|
Loans |
|
25,681 |
24,311 |
|
Trade and other payables |
|
57,343 |
48,251 |
|
Foreign exchange derivatives |
|
824 |
- |
|
Income tax payable |
|
5,969 |
4,074 |
|
Provisions |
|
87 |
85 |
|
|
|
89,904 |
76,721 |
|
Non-current liabilities |
|
|
|
|
Loans |
|
58,045 |
78,958 |
|
Trade and other payables |
|
318 |
- |
|
Provisions |
|
843 |
645 |
|
Deferred tax liabilities |
|
30,700 |
30,017 |
|
|
|
89,906 |
109,620 |
|
Total liabilities |
3 |
179,810 |
186,341 |
|
Total net assets |
|
397,496 |
355,279 |
|
Equity |
|
|
|
|
Capital and reserves attributable to owners of the Parent |
|
|
|
|
Share capital |
|
2,737 |
2,735 |
|
Share premium |
|
51,757 |
51,549 |
|
Share based payment reserve |
|
662 |
384 |
|
Reverse acquisition reserve |
|
(8,483) |
(8,483) |
|
Foreign currency reserve |
|
29,082 |
8,941 |
|
Hedge reserve |
|
(2,253) |
408 |
|
Retained earnings |
|
323,994 |
299,745 |
|
Total equity |
|
397,496 |
355,279 |
Consolidated Statement of Changes in Equity
for the year ended 30 September 2019
|
|
Notes |
Share capital £'000 |
Share premium account |
Other reserves |
Retained earnings |
Total attributable to owners of Parent |
|
At 1 October 2017 |
|
2,293 |
50,718 |
(2,542) |
108,416 |
158,885 |
|
|
|
|
|
|
|
|
|
Profit for the year |
|
- |
- |
- |
28,257 |
28,257 |
|
Gain on cash flow hedges |
|
- |
- |
408 |
- |
408 |
|
Gain on retranslation of foreign operations |
|
- |
- |
3,526 |
- |
3,526 |
|
Total comprehensive income for the year |
|
- |
- |
3,934 |
28,257 |
32,191 |
|
|
|
|
|
|
|
|
|
Issue of shares |
|
442 |
831 |
- |
184,565 |
185,838 |
|
Share issue costs |
|
- |
- |
- |
(3,631) |
(3,631) |
|
Deferred tax on unexercised share options |
|
- |
- |
- |
150 |
150 |
|
Income tax on unexercised share options |
|
- |
- |
- |
153 |
153 |
|
Dividends |
5 |
- |
- |
- |
(18,307) |
(18,307) |
|
Exercise of share options |
|
- |
- |
(142) |
142 |
- |
|
|
|
|
|
|
|
|
|
At 30 September 2018 |
|
2,735 |
51,549 |
1,250 |
299,745 |
355,279 |
|
|
|
|
|
|
|
|
|
Profit for the year |
|
- |
- |
- |
45,140 |
45,140 |
|
Loss on cash flow hedges |
|
- |
- |
(2,661) |
- |
(2,661) |
|
Gain on retranslation of foreign operations |
|
- |
- |
20,141 |
- |
20,141 |
|
Total comprehensive income for the year |
|
- |
- |
17,480 |
45,140 |
62,620 |
|
|
|
|
|
|
|
|
|
Issue of shares |
|
2 |
208 |
- |
- |
210 |
|
Deferred tax on unexercised share options |
|
- |
- |
- |
145 |
145 |
|
Income tax on unexercised share options |
|
- |
- |
- |
131 |
131 |
|
Dividends |
5 |
- |
- |
- |
(21,200) |
(21,200) |
|
Exercise of share options |
|
- |
- |
(33) |
33 |
- |
|
Equity-settled share based payments |
|
- |
- |
311 |
- |
311 |
|
|
|
|
|
|
|
|
|
At 30 September 2019 |
|
2,737 |
51,757 |
19,008 |
323,994 |
397,496 |
|
|
|
|
|
|
|
|
|
Other reserves |
|
Share based payment reserve £'000 |
Reverse acquisition reserve |
Hedge reserve |
Foreign currency reserve |
Total other reserves |
|
At 1 October 2017 |
|
526 |
(8,483) |
- |
5,415 |
(2,542) |
|
|
|
|
|
|
|
|
|
Other comprehensive loss for the year |
|
- |
- |
408 |
3,526 |
3,934 |
|
Exercise of share options |
|
(142) |
- |
- |
- |
(142) |
|
|
|
|
|
|
|
|
|
At 30 September 2018 |
|
384 |
(8,483) |
408 |
8,941 |
1,250 |
|
|
|
|
|
|
|
|
|
Other comprehensive income for the year |
|
- |
- |
(2,661) |
20,141 |
17,480 |
|
Exercise of share options |
|
(33) |
- |
- |
- |
(33) |
|
Equity-settled share based payments |
|
311 |
- |
- |
- |
311 |
|
|
|
|
|
|
|
|
|
At 30 September 2019 |
|
662 |
(8,483) |
(2,253) |
29,082 |
19,008 |
Consolidated Statement of Cash Flows
for the year ended 30 September 2019
|
|
Note |
2019 |
20181 |
|
Cash flows from operating activities |
|
|
|
|
Profit before tax |
|
57,717 |
39,659 |
|
Adjustments for: |
|
|
|
|
Depreciation of property, plant and equipment |
|
3,025 |
2,786 |
|
Amortization of intangible assets |
|
18,364 |
16,617 |
|
Share based payment expense |
|
311 |
- |
|
Finance income |
|
(105) |
(69) |
|
Finance expense |
|
4,268 |
4,541 |
|
Operating cash flow before movements in working capital and provisions |
|
83,580 |
63,534 |
|
Increase in trade and other receivables |
|
(11,523) |
(6,488) |
|
Increase/(decrease) in trade and other payables and provisions |
|
9,770 |
(570) |
|
Cash generated from operations |
|
81,827 |
56,476 |
|
Income tax paid |
|
(11,464) |
(12,848) |
|
Net cash inflow from operating activities |
|
70,363 |
43,628 |
|
Cash flows from investing activities |
|
|
|
|
Interest received |
|
105 |
69 |
|
Acquisition of subsidiary, net of cash acquired |
|
(4,536) |
(242,311) |
|
Purchases of property, plant and equipment |
|
(3,844) |
(1,872) |
|
Purchases of intangibles (computer software) |
|
(4,170) |
(3,320) |
|
Net cash outflow from investing activities |
|
(12,445) |
(250,955) |
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
Proceeds from borrowings |
|
- |
118,591 |
|
Repayment of borrowings |
|
(25,057) |
(58,140) |
|
Interest paid |
|
(4,125) |
(3,521) |
|
Proceeds from the issue of share capital |
|
209 |
182,207 |
|
Dividends paid |
5 |
(21,200) |
(18,307) |
|
Net cash (outflow)/inflow from financing activities |
|
(50,173) |
224,351 |
|
Net increase in cash and cash equivalents |
|
7,745 |
17,024 |
|
Cash and cash equivalents at beginning of the year |
|
38,155 |
20,064 |
|
Exchange gains/(losses) on cash and cash equivalents |
|
1,074 |
1,067 |
|
Cash and cash equivalents at end of the year |
|
46,974 |
38,155 |
|
|
|
|
|
|
Free cash flow |
|
|
|
|
Analysis of free cash flow |
|
|
|
|
Cash generated from operations |
|
81,827 |
56,476 |
|
Net interest paid |
|
(4,020) |
(3,452) |
|
Income tax paid |
|
(11,464) |
(12,848) |
|
Purchases of property, plant and equipment |
|
(3,844) |
(1,872) |
|
Purchases of intangibles (computer software) |
|
(4,170) |
(3,320) |
|
Free cash flow |
|
58,329 |
34,984 |
1 Interest paid has been reclassified from "cash flows from investing activities" to "cash flows from financing activities"
The Directors consider that the free cash flow analysis above indicates the cash generated from normal activities excluding acquisitions, dividends paid and the proceeds from the issue of share capital.
Notes to the
Consolidated Financial Statements
1. GENERAL INFORMATION
RWS Holdings plc ("the Parent Company") is a public limited company incorporated and domiciled in England and Wales whose shares are publicly traded on AIM, the London Stock Exchange regulated market.
The consolidated financial statements consolidate those of the Parent Company and its subsidiaries ("the Group"). The Group's consolidated financial statements, from which this financial information has been extracted, have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU, IFRS IC interpretations and the Companies Act 2006 applicable to Companies reporting under IFRS.
The financial information shown in the announcement for the year ended 30 September 2019 and the year ended 30 September 2018 set out above does not constitute statutory accounts but is derived from those accounts. Except as described below, the principal accounting policies applied in the preparation of the consolidated financial statements are consistent with those of the annual financial statements for the year ended 30 September 2018, as described in those financial statements.. The financial information contained in this announcement does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. Statutory accounts for the year ended 30 September 2018 have been delivered to the Registrar of Companies and those for the year ended 30 September 2019 will be delivered shortly, having been approved by the Directors on 9 December 2019. The auditors have reported on the accounts for the years ended 30 September 2018 and 30 September 2019, their reports were unqualified, did not contain statements under Section 498 (2) or (3) of the Companies Act 2006 and did not contain any matters to which the auditors drew attention without qualifying their report.
Copies of this announcement are available at the registered office of the Company for a period of 14 days from the date hereof.
Notes to the
Consolidated Financial Statements
2. ACCOUNTING POLICIES
The principal accounting policies adopted in the preparation of the Group's consolidated financial statements have been consistently applied to both years presented and the financial statements for the years presented, with the exception of the adoption of two new standards:
- IFRS 9 "Financial Instruments" (effective 1 October 2018). It has been determined that all existing effective hedging instruments continued to qualify for hedge accounting under IFRS 9. Changes to the classification, impairment and measurement of financial assets and liabilities have all been considered and it has been concluded that these changes do not have a material impact on the Group.
- IFRS 15 "Revenue from contracts with customers" (effective 1 October 2018). An assessment was carried out on whether the new standard impacted the recognition or measurement of any of the Group's revenue streams, but ultimately it has been concluded that there is no material impact on the Group's existing revenue recognition policies.
IFRS 16 Leases supersedes IAS 17 Leases and has been endorsed for use by the European Union. The most significant changes arising from IFRS 16 are in relation to lessee accounting, where lessees must recognize a right-of-use ("RoU") asset and a lease liability for all leases currently accounted for as operating leases, except for, leases for a short period (less than 12 months) or where the underlying asset value is considered to be low.
IFRS 16 will have a significant impact on the primary financial statements of the Group, principally impacting total assets and total liabilities, but also having an impact on operating profit, profit before tax.
The Group intends to take advantage of the modified retrospective transition method where the lease liability is recognized as the present value of future payments as at transition date, and the RoU asset is recognized as the present value of the total lease payments at lease inception and then depreciated on a straight-line basis from this date until transition date. As such a transition adjustment arises due to the difference between the value of the asset and the liability which is taken to retained earnings, net of any reclassification of rent prepayments, rent accruals or lease incentives.
Based on the Group's review of its lease contracts in place at 1 October 2019, the Group expects to recognize RoU assets of £23.2 million and lease liabilities of £24.5 million. The Group is finalizing its work in respect of any deferred tax impact regarding these transitional adjustments.
From an income statement perspective, profit before tax is expected to be £0.2 million lower in FY2020, while operating profit is expected to be £0.4 million higher.
Notes to the
Consolidated Financial Statements
2. ACCOUNTING POLICIES - CONTINUED
There is not expected to be any significant impact to the Group's cash flows, however the classification within the statement of cash flows will change. It is estimated that the Group's operating cash inflows will increase, and its financing outflows increase by approximately £4.7 million as the repayment of the principal portion of the lease liabilities will be classified as cash flows from financing activities.
The Group's activities as a lessor are currently not material.
The consolidated financial statements consolidate those of the Parent Company and its subsidiaries ("the Group"). The Group's consolidated financial statements, from which this financial information has been extracted, have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU, IFRS IC interpretations and the Companies Act 2006 applicable to Companies reporting under IFRS.
3. REVENUE FROM CONTRACTS WITH CUSTOMERS AND SEGMENT INFORMATION
A Revenue from contracts with customers
The Group generates all revenue from contracts with its customers for the provision of translation and localization, intellectual property support solutions and life sciences language services. Revenue from providing these services during the year is recognized both at a point in time and over time as shown in the table below:
|
Timing of revenue recognition for contracts with customers |
2019 |
2018 |
|
|
|
|
|
At a point in time |
300,315 |
256,177 |
|
Over time |
55,381 |
49,927 |
|
Total revenue from contracts with customers |
355,696 |
306,044 |
Notes to the
Consolidated Financial Statements
3. REVENUE FROM CONTRACTS WITH CUSTOMERS AND SEGMENT INFORMATION - CONTINUED
The following table disaggregates the Group's revenues from contracts with customers accordingly to the line of service provided
|
Revenue by line of service provided |
2019 |
2018 |
|
|
|
|
|
Patent translation services |
85,589 |
74,288 |
|
Patent filing fees |
29,467 |
27,968 |
|
PatBase subscriptions |
5,615 |
5,278 |
|
IP support services |
4,569 |
4,415 |
|
IP Services |
125,240 |
111,949 |
|
|
|
|
|
Localization services |
119,904 |
97,690 |
|
Managed services |
29,976 |
29,180 |
|
Moravia |
149,880 |
126,870 |
|
|
|
|
|
Life Sciences translation services |
45,173 |
36,834 |
|
Linguistic validation services |
20,293 |
15,469 |
|
Life Sciences |
65,466 |
52,303 |
|
|
|
|
|
Corporate translation services |
15,110 |
14,922 |
|
Language Solutions |
15,110 |
14,922 |
|
|
|
|
|
Total revenue from contracts with customers |
355,696 |
306,044 |
The following table provides information about receivables, accrued income and deferred income from contracts with customers.
|
Receivables, accrued and deferred income |
Note |
2019 |
2018 |
|
|
|
|
|
|
Net trade receivables |
|
69,244 |
61,102 |
|
Accrued income |
|
9,642 |
6,741 |
|
Deferred income |
|
(3,079) |
(2,960) |
Accrued income relates to the Group's right to consideration for work completed and delivered but not invoiced as at year end and is transferred to trade receivables when an invoice is issued to the client. Clients are typically invoiced on a monthly basis and consideration is payable when invoiced. During the year £6,741,000 of accrued income was invoiced in the period ended 30 September 2019.
Notes to the
Consolidated Financial Statements
3. REVENUE FROM CONTRACTS WITH CUSTOMERS AND SEGMENT INFORMATION - CONTINUED
Deferred income relates to advance consideration received from customers for PatBase subscriptions and linguistic validation projects, where revenue is recognized over time as the services are provided/delivered to clients. During the year, £2,960,000 of deferred revenue at the beginning of the period has been recognized as revenue for the period ended 30 September 2019.
B Segment information
The chief operating decision maker has been identified as the Board. The Board reviews the Group's internal reporting in order to assess performance and allocate resources. The Board divides the Group into four reportable segments and assesses the performance of each segment based on revenue and profit/(loss) from operations. These are measured on a basis consistent with the statement of comprehensive income.
In the year ended 30 September 2018, there were five reportable segments; Patent Information, which was previously shown separately, is now included within IP Services.
From 1 October 2019, the RWS Language Solutions segment was merged into the RWS Moravia segment, which will result in the Group having three reportable segments for the year ended 30 September 2020.
The four segments are:
> RWS IP Services provides the highest quality patent translations, a seamless global patent filing experience and a wide range of cutting-edge intellectual property (IP) search services.
> RWS Life Sciences: provides a full suite of language services, including technical translations and linguistic validation, exclusively for the life sciences industry.
> RWS Moravia: provides localization services including the adaptation of content, software, websites, applications, marketing material and audio/video to ensure brand consistency.
> RWS Language Solutions: provides a full range of translation and interpreting services to help businesses communicate globally.
Notes to the
Consolidated Financial Statements
3. REVENUE FROM CONTRACTS WITH CUSTOMERS AND SEGMENT INFORMATION - CONTINUED
The unallocated segment relates to corporate overheads, assets and liabilities.
|
Segment results for the year ended 30 September 2019 |
|
IP Services |
Life Sciences |
Moravia |
Language Solutions |
Unallocated |
Group |
|
|
|||||||
|
Revenue from contracts with customers |
|
125,240 |
65,466 |
149,880 |
15,110 |
- |
355,696 |
|
|
|
|
|
|
|
|
|
|
Operating profit/(loss) before charging: |
|
36,119 |
20,327 |
25,747 |
434 |
(4,231) |
78,396 |
|
Amortization of acquired intangibles |
|
(674) |
(6,036) |
(8,565) |
(139) |
- |
(15,414) |
|
Acquisition costs |
|
- |
- |
- |
(195) |
(596) |
(791) |
|
Share-based payments expense |
|
(74) |
- |
(36) |
(22) |
(179) |
(311) |
|
Profit/(loss) from operations |
|
35,371 |
14,291 |
17,146 |
78 |
(5,006) |
61,880 |
|
Finance income |
|
|
|
|
|
|
105 |
|
Finance expense |
|
|
|
|
|
|
(4,268) |
|
Profit before taxation |
|
|
|
|
|
|
57,717 |
|
Taxation |
|
|
|
|
|
|
(12,577) |
|
Profit for the year |
|
|
|
|
|
|
45,140 |
|
Segment results for the year ended 30 September 2018 |
|
IP Services |
Life Sciences |
Moravia |
Language Solutions |
Unallocated |
Group |
|
|
|||||||
|
Revenue from contracts with customers |
|
111,949 |
52,303 |
126,870 |
14,922 |
- |
306,044 |
|
Operating profit/(loss) before charging: |
|
34,404 |
14,548 |
16,980 |
1,566 |
(1,188) |
66,310 |
|
Amortization of acquired intangibles |
|
(1,119) |
(5,898) |
(7,415) |
(159) |
- |
(14,591) |
|
Acquisition costs |
|
- |
- |
(966) |
- |
(6,622) |
(7,588) |
|
Profit/(loss) from operations |
|
33,285 |
8,650 |
8,599 |
1,407 |
(7,810) |
44,131 |
|
Finance income |
|
|
|
|
|
|
69 |
|
Finance expense |
|
|
|
|
|
|
(4,541) |
|
Profit before taxation |
|
|
|
|
|
|
39,659 |
|
Taxation |
|
|
|
|
|
|
(11,402) |
|
Profit for the year |
|
|
|
|
|
|
28,257 |
Notes to the
Consolidated Financial Statements
3. REVENUE FROM CONTRACTS WITH CUSTOMERS AND SEGMENT INFORMATION - CONTINUED
|
Segment assets and liabilities at 30 September 2019 |
|
IP Services |
Life Sciences |
Moravia |
Language Solutions |
Unallocated |
Group |
|
|
|
|
|||||||
|
Total assets |
|
105,453 |
138,676 |
312,985 |
16,526 |
3,666 |
577,306 |
|
|
Total liabilities |
|
23,009 |
44,636 |
105,979 |
2,270 |
3,916 |
179,810 |
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditure |
|
758 |
349 |
6,693 |
85 |
159 |
8,044 |
|
|
Depreciation |
|
582 |
259 |
1,903 |
103 |
178 |
3,025 |
|
|
Amortization |
|
747 |
6,095 |
11,356 |
156 |
10 |
18,364 |
|
|
Segment assets and liabilities at 30 September 2018 |
|
IP Services |
Life Sciences |
Moravia |
Language Solutions |
Unallocated |
Group |
|
|
|
|
|||||||
|
Total assets |
|
87,552 |
130,779 |
300,376 |
13,519 |
9,394 |
541,620 |
|
|
Total liabilities |
|
18,631 |
49,366 |
113,979 |
2,200 |
2,165 |
186,341 |
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditure |
|
199 |
205 |
12,828 |
117 |
301 |
13,650 |
|
|
Depreciation |
|
639 |
211 |
1,690 |
118 |
128 |
2,786 |
|
|
Amortization |
|
1,191 |
5,902 |
9,298 |
181 |
45 |
16,617 |
|
Capital expenditure comprises additions to property, plant and equipment and intangible assets, including additions from acquisitions through business combinations.
|
Assets and liabilities are reconciled to the Group's assets and liabilities as follows: |
Assets |
Liabilities |
Assets |
Liabilities |
|
Total segment assets and liabilities |
573,640 |
175,894 |
532,226 |
184,176 |
|
Unallocated: |
|
|
|
|
|
Deferred tax |
1,063 |
1,509 |
880 |
37 |
|
Property, plant and equipment |
302 |
- |
321 |
- |
|
Non-financial assets |
999 |
2,198 |
732 |
1,833 |
|
Other financial assets and liabilities |
- |
209 |
- |
295 |
|
Cash and cash equivalents |
1,302 |
- |
7,461 |
- |
|
Total unallocated assets and liabilities |
3,666 |
3,916 |
9,394 |
2,165 |
|
|
|
|
|
|
|
Total Group assets and liabilities |
577,306 |
179,810 |
541,620 |
186,341 |
Assets allocated to a segment consist primarily of operating assets such as property, plant and equipment, intangible assets, goodwill, receivables and cash.
Liabilities allocated to a segment comprise primarily bank loans, trade and other payables.
Notes to the
Consolidated Financial Statements
3. REVENUE FROM CONTRACTS WITH CUSTOMERS AND SEGMENT INFORMATION - CONTINUED
The Group's operations are based in the UK, Continental Europe, Asia, the United States, Argentina and Australia. The table below shows turnover by the geographic market in which clients are located.
|
Turnover by client location |
2019 |
2018 |
|
UK |
29,791 |
24,298 |
|
Continental Europe |
108,770 |
101,708 |
|
United States |
190,807 |
163,941 |
|
Rest of the world |
26,328 |
16,097 |
|
|
355,696 |
306,044 |
One client accounted for more than 10% of Group turnover in the current year (2018: one). This client was part of the Moravia reporting segment.
The following is an analysis of revenue and non-current assets analyzed by the geographical area in which the Group's undertakings are located.
|
|
Revenue |
Non-Current assets |
||
|
|
2019 £'000 |
2018 |
2019 |
2018 |
|
UK |
123,770 |
112,650 |
28,397 |
29,192 |
|
Continental Europe |
84,134 |
79,209 |
276,058 |
264,362 |
|
United States |
138,730 |
109,385 |
130,867 |
133,941 |
|
Rest of the world |
9,062 |
4,800 |
6,096 |
219 |
|
|
355,696 |
306,044 |
441,418 |
427,714 |
4. TAXATION
|
|
2019 |
2018 |
|
|
|
|
|
Taxation recognized in the income statement is as follows: |
|
|
|
Current tax expense |
|
|
|
Tax on profit for the current year |
|
|
|
- UK |
6,228 |
6,641 |
|
- Overseas |
8,815 |
6,275 |
|
Adjustments in respect of prior years |
(824) |
(261) |
|
|
14,219 |
12,655 |
|
Deferred tax |
|
|
|
Current year movement |
(1,715) |
(1,464) |
|
Adjustments in respect of prior years |
73 |
211 |
|
Total tax expense for the year |
12,577 |
11,402 |
Notes to the
Consolidated Financial Statements
5. DIVIDENDS TO SHAREHOLDERS
|
|
2019 |
2019 |
2018 |
2018 |
|
|
|
|
|
|
|
Final, paid 22 February 2019 (2018: paid 23 February 2018) |
6.00 |
16,413 |
5.20 |
14,209 |
|
Interim, paid 19 July 2019 (2018: paid 20 July 2018) |
1.75 |
4,787 |
1.50 |
4,098 |
|
|
7.75 |
21,200 |
6.70 |
18,307 |
The Directors recommend a final dividend in respect of the financial year ended 30 September 2019 of 7.00 pence per ordinary share, to be paid on 21 February 2020 to shareholders who are on the register at 24 January 2020. This dividend is not reflected in these financial statements as it does not represent a liability at 30 September 2019. The final proposed dividend will reduce shareholders' funds by an estimated £19.2m.
6. EARNINGS PER ORDINARY SHARE
Basic earnings per share is calculated using the Group's profit after tax and the weighted average number of ordinary shares in issue during the year, as follows:
|
|
2019 |
2018 |
|
|
|
|
|
Weighted average number of ordinary shares in issue for basic earnings |
273,556,236 |
271,216,566 |
|
Dilutive impact of share options |
1,250,343 |
1,265,706 |
|
Weighted average number of ordinary shares for diluted earnings |
274,806,579 |
272,482,272 |
Notes to the
Consolidated Financial Statements
6. EARNINGS PER SHARE - CONTINUED
The reconciliation between the basic and adjusted figures is as follows:
|
|
2019 |
2018 |
2019 |
2018 |
2019 |
2018 |
|
|
|
|
|
|
|
|
|
Profit for the year |
45,140 |
28,257 |
16.5 |
10.4 |
16.4 |
10.4 |
|
Adjustments: |
|
|
|
|
|
|
|
Amortization of acquired intangibles |
15,414 |
14,591 |
5.6 |
5.4 |
5.6 |
5.3 |
|
Acquisition costs |
791 |
7,588 |
0.3 |
2.8 |
0.3 |
2.8 |
|
Charges for share based payments |
311 |
- |
0.1 |
- |
0.1 |
- |
|
Tax effect of adjustments |
(3,176) |
(3,285) |
(1.2) |
(1.2) |
(1.2) |
(1.2) |
|
Adjusted earnings |
58,480 |
47,151 |
21.3 |
17.4 |
21.2 |
17.3 |
RWS uses adjusted results as a key performance indicator, as the Directors believe that these provide a more consistent measure of the Group's operating performance. Adjusted profit is therefore stated before amortization of acquired intangibles, acquisition costs and share option costs, net of any associated tax effects.
[1] RWS uses adjusted results as key performance indicators as the Directors believe that these provide a more consistent measure of operating performance by adjusting for acquisition related charges and significant one-off or non-cash items. Adjusted operating profit is stated before interest, amortization of acquired intangibles, share option costs and acquisition costs. Adjusted profit before tax is stated before amortization of acquired intangibles, share option costs and acquisition costs. Adjusted earnings per share adjusts for amortization of acquired intangibles, share option costs and acquisitions costs, net of any associated tax effects. Net debt is calculated as total loans less cash and cash equivalents.
[2] All references to "underlying" exclude the impact of acquisitions and assume constant currency.
[3] EBITDA represents the Group's profits before interest, tax, depreciation and amortization.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund